Understand the mechanism of action for OPDIVO®(nivolumab), YERVOY®(ipilimumab) and Opdualag®
Opdualag: Fixed-dose combination (FDC) of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3).
Nivolumab: Blocks PD-1 receptor on T-cells, preventing interaction with PD-L1/PD-L2. Restores
T-cell activity and enhances the anti-tumor immune response.
Relatlimab: Targets LAG-3 receptor, reducing its inhibitory effect on T-cells. Further boosts T-cell activity.
Combined effect: Dual blockade of PD-1 and LAG-3 increases T-cell activation more than either antibody alone. Results in reduced tumor growth and enhanced tumor regression in preclinical models.
See the mode of action video 2.32 sec and get and understanding of the mechanism of action for Opdivo, Yervoy and Opdualag1,2,3
Reference:
1425-SE-2500009 February 2025
We refer to the SmPC for full information on Opdualag®